Biological Products, (No Diagnostic Substances) Industry - SEC Form 4 Insider Trading Screener
Manufacturing Sector - Chemicals - Biological Products, (No Diagnostic Substances)
100 results - 
- 
- 
- 
- 
- 
- 
- - - - - - | TC | cnt | 1d | 1w | 1m | 6m |
X |
Filing Date |
Trade Date |
Ticker |
Company | Insider Name | Insider Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2018-09-21 | BCDA | Biocardia, Inc. | Stertzer Simon H | Dir | P - Purchase | $2.43 | +1,000 | 3,573,094 | 0% | +$2,430 | ||||||
| M | 2018-09-12 | BCDA | Biocardia, Inc. | Altman Peter | Pres, CEO | P - Purchase | $1.74 | +1,100 | 714,442 | 0% | +$1,914 | |||||
| M | 2018-08-29 | GNCA | Genocea Biosciences, Inc. | Siber George | Dir | P - Purchase | $0.61 | +163,400 | 165,417 | >999% | +$100,174 | |||||
| M | 2018-09-19 | LIFE | Atyr Pharma Inc | Broadfoot Jill Marie | CFO | P - Purchase | $0.83 | +64,000 | 90,000 | +246% | +$52,855 | |||||
| M | 2018-09-18 | BCDA | Biocardia, Inc. | Altman Peter | Pres, CEO | P - Purchase | $1.65 | +700 | 713,342 | 0% | +$1,154 | |||||
2018-09-18 | BCDA | Biocardia, Inc. | Stertzer Simon H | Dir | P - Purchase | $1.50 | +5,000 | 3,572,094 | 0% | +$7,500 | ||||||
| D | 2018-09-18 | BOLD | Audentes Therapeutics, Inc. | Patterson Matthew R | CEO | S - Sale+OE | $40.00 | -12,952 | 171,814 | -7% | -$518,080 | |||||
| M | 2018-09-18 | ATRA | Atara Biotherapeutics, Inc. | Ciechanover Isaac E. | CEO | S - Sale | $39.80 | -7,800 | 871,291 | -1% | -$310,479 | |||||
| D | 2018-09-17 | SGEN | Seattle Genetics Inc /wa | Siegall Clay B | Pres, CEO | S - Sale+OE | $76.84 | -20,148 | 732,613 | -3% | -$1,548,196 | |||||
| D | 2018-09-17 | NSTG | Nanostring Technologies Inc | Clarus Lifesciences Ii, L.P. | 10% | S - Sale+OE | $15.99 | -85,823 | 4,036,025 | -2% | -$1,372,310 | |||||
| D | 2018-09-17 | NSTG | Nanostring Technologies Inc | Galakatos Nicholas | Dir, 10% | S - Sale+OE | $15.99 | -85,823 | 4,036,025 | -2% | -$1,372,310 | |||||
| D | 2018-09-17 | RGNX | Regenxbio Inc. | Vasista Vittal | CFO | S - Sale+OE | $74.86 | -7,500 | 144,783 | -5% | -$561,472 | |||||
2018-09-17 | RGNX | Regenxbio Inc. | Mills Kenneth T. | Pres, CEO | S - Sale | $74.91 | -7,510 | 333,510 | -2% | -$562,564 | ||||||
| DM | 2018-09-17 | EDIT | Editas Medicine, Inc. | Myer Vickesh | CTO | S - Sale+OE | $32.25 | -7,000 | 0 | -100% | -$225,750 | |||||
2018-09-18 | PTE | Polarityte, Inc. | Swanson Edward Winslow | COO | P - Purchase | $17.27 | +500 | 1,689 | +42% | +$8,633 | ||||||
2018-09-18 | PTE | Polarityte, Inc. | Mann Paul Elliot | CFO | P - Purchase | $17.24 | +20,000 | 120,000 | +20% | +$344,716 | ||||||
| M | 2018-09-14 | BCDA | Biocardia, Inc. | Altman Peter | Pres, CEO | P - Purchase | $1.59 | +700 | 712,642 | 0% | +$1,110 | |||||
2018-09-14 | LIFE | Atyr Pharma Inc | Broadfoot Jill Marie | CFO | P - Purchase | $0.73 | +26,000 | 26,000 | New | +$19,055 | ||||||
| D | 2018-09-17 | SGMO | Sangamo Therapeutics, Inc | Yi Kathy | SVP, CFO | S - Sale+OE | $14.66 | -5,000 | 7,250 | -41% | -$73,285 | |||||
2018-09-18 | ONS | Oncobiologics, Inc. | Kenyon Lawrence A | CEO, Pres, CFO, Treas, Secy | S - Sale | $0.87 | -10,100 | 57,213 | -15% | -$8,807 | ||||||
2018-09-14 | PTE | Polarityte, Inc. | Erdtmann Rainer M | Dir | P - Purchase | $17.42 | +6,680 | 81,846 | +9% | +$116,366 | ||||||
2018-09-14 | AERI | Aerie Pharmaceuticals Inc | Rubino Richard J | CFO | S - Sale | $60.00 | -2 | 383,736 | 0% | -$120 | ||||||
2018-09-13 | HSKA | Heska Corp | Napolitano Jason A | COO, Chief Strategist, Sec. | S - Sale | $111.50 | -2,500 | 26,974 | -8% | -$278,750 | ||||||
2018-09-13 | GNCA | Genocea Biosciences, Inc. | Alfieri Michael | Principle Financial Officer | P - Purchase | $0.54 | +10,000 | 10,000 | New | +$5,400 | ||||||
2018-09-13 | AERI | Aerie Pharmaceuticals Inc | Rubino Richard J | CFO | S - Sale | $60.17 | -34,512 | 383,738 | -8% | -$2,076,608 | ||||||
| D | 2018-09-11 | BTX | Biotime Inc | Andrews Deborah J | Dir | P - Purchase | $2.35 | +1,604 | 10,000 | +19% | +$3,769 | |||||
2018-09-10 | VYGR | Voyager Therapeutics, Inc. | Geraghty James A | Dir | P - Purchase | $19.39 | +3,000 | 76,588 | +4% | +$58,170 | ||||||
2018-09-12 | VYGR | Voyager Therapeutics, Inc. | Pierce Glenn | Dir | P - Purchase | $18.44 | +5,000 | 5,000 | New | +$92,200 | ||||||
| M | 2018-09-10 | BCDA | Biocardia, Inc. | Altman Peter | Pres, CEO | P - Purchase | $1.36 | +1,600 | 711,942 | 0% | +$2,184 | |||||
| D | 2018-09-10 | RGEN | Repligen Corp | Hunt Anthony | CEO | S - Sale+OE | $57.71 | -27,566 | 227,451 | -11% | -$1,590,809 | |||||
| D | 2018-09-10 | BLUE | Bluebird Bio, Inc. | Walsh Jeffrey T. | Chief Financial | S - Sale+OE | $150.16 | -1,500 | 35,495 | -4% | -$225,243 | |||||
2018-09-10 | BLUE | Bluebird Bio, Inc. | Mandell James | Dir | S - Sale | $150.77 | -1,000 | 1,000 | -50% | -$150,771 | ||||||
| D | 2018-09-10 | CHRS | Coherus Biosciences, Inc. | Finck Barbara K | Chief Medical Officer | S - Sale+OE | $18.58 | -1,760 | 37,043 | -5% | -$32,699 | |||||
| D | 2018-09-10 | VCEL | Vericel Corp | Michel Gerard J | CFO, VP, Corp. Development | S - Sale+OE | $12.35 | -15,000 | 150,960 | -9% | -$185,250 | |||||
| D | 2018-09-07 | SGEN | Seattle Genetics Inc /wa | Himes Vaughn B | Chief Technical Officer | S - Sale+OE | $76.99 | -5,000 | 177,329 | -3% | -$384,962 | |||||
2018-07-27 | ATRA | Atara Biotherapeutics, Inc. | Koppikar Utpal | CFO | P - Purchase | $36.80 | +2,000 | 47,000 | +4% | +$73,600 | ||||||
2018-09-07 | ADAP | Adaptimmune Therapeutics Plc | Viswanathan Ravi | 10% | P - Purchase | $1.67 | +15,000,000 | 94,978,668 | +19% | +$25,000,500 | ||||||
2018-09-07 | ADAP | Adaptimmune Therapeutics Plc | Sonsini Peter W. | 10% | P - Purchase | $1.67 | +15,000,000 | 94,978,668 | +19% | +$25,000,500 | ||||||
2018-09-07 | ADAP | Adaptimmune Therapeutics Plc | Sandell Scott D | 10% | P - Purchase | $1.67 | +15,000,000 | 94,978,668 | +19% | +$25,000,500 | ||||||
2018-09-07 | ADAP | Adaptimmune Therapeutics Plc | Mott David M | Dir, 10% | P - Purchase | $1.67 | +15,000,000 | 94,978,668 | +19% | +$25,000,500 | ||||||
2018-09-07 | ADAP | Adaptimmune Therapeutics Plc | Kerins Patrick J | 10% | P - Purchase | $1.67 | +3,000,000 | 82,978,668 | +4% | +$5,000,100 | ||||||
2018-09-07 | ADAP | Adaptimmune Therapeutics Plc | Florence Anthony A. Jr. | 10% | P - Purchase | $1.67 | +15,000,000 | 94,978,668 | +19% | +$25,000,500 | ||||||
2018-09-07 | ADAP | Adaptimmune Therapeutics Plc | Behbahani Ali | Dir | P - Purchase | $1.67 | +12,000,000 | 12,000,000 | New | +$20,000,400 | ||||||
2018-09-07 | ADAP | Adaptimmune Therapeutics Plc | Baskett Forest | 10% | P - Purchase | $1.67 | +15,000,000 | 94,978,668 | +19% | +$25,000,500 | ||||||
2018-09-07 | ADAP | Adaptimmune Therapeutics Plc | Barris Peter J | 10% | P - Purchase | $1.67 | +15,000,000 | 94,978,668 | +19% | +$25,000,500 | ||||||
2018-09-07 | ADAP | Adaptimmune Therapeutics Plc | Barrett M James | 10% | P - Purchase | $1.67 | +3,000,000 | 82,978,668 | +4% | +$5,000,100 | ||||||
2018-09-07 | ADAP | Adaptimmune Therapeutics Plc | New Enterprise Associates 14, L.P. | 10% | P - Purchase | $1.67 | +3,000,000 | 82,978,668 | +4% | +$5,000,100 | ||||||
| M | 2018-09-06 | ATRA | Atara Biotherapeutics, Inc. | Ciechanover Isaac E. | CEO | S - Sale | $39.35 | -7,800 | 879,091 | -1% | -$306,923 | |||||
2018-09-07 | SGMO | Sangamo Therapeutics, Inc | Jeffs Roger | Dir | P - Purchase | $13.56 | +7,408 | 9,908 | +296% | +$100,487 | ||||||
2018-09-07 | SGMO | Sangamo Therapeutics, Inc | Parker H Stewart | Dir | P - Purchase | $13.52 | +2,000 | 5,500 | +57% | +$27,040 | ||||||
| D | 2018-09-06 | SGMO | Sangamo Therapeutics, Inc | Conner Edward R. | SVP, Chief Medical Officer | S - Sale+OE | $14.17 | -5,000 | 10,125 | -33% | -$70,845 | |||||
| D | 2018-09-05 | BLUE | Bluebird Bio, Inc. | Gregory Philip D | Chief Scientific Officer | S - Sale+OE | $163.02 | -1,800 | 31,871 | -5% | -$293,441 | |||||
2018-09-04 | DNLI | Denali Therapeutics Inc. | Ho Carole | Chief Medical Officer | S - Sale | $19.05 | -17,500 | 272,765 | -6% | -$333,375 | ||||||
2018-09-04 | DNLI | Denali Therapeutics Inc. | Watts Ryan J. | Pres, CEO | S - Sale | $19.06 | -18,333 | 2,778,476 | -1% | -$349,427 | ||||||
| D | 2018-09-04 | GILD | Gilead Sciences Inc | Martin John C | Dir | S - Sale+OE | $74.16 | -50,000 | 3,017,762 | -2% | -$3,708,034 | |||||
2018-09-04 | AERI | Aerie Pharmaceuticals Inc | Kopczynski Casey C. | Chief Scientific Officer | S - Sale | $60.09 | -11,000 | 147,517 | -7% | -$661,024 | ||||||
| M | 2018-08-28 | ACOR | Acorda Therapeutics Inc | Scopia Capital Management LP | 10% | S - Sale | $28.76 | -34,285 | 7,106,955 | 0% | -$986,141 | |||||
| D | 2018-09-04 | BLUE | Bluebird Bio, Inc. | Davidson David | Chief Medical Officer | S - Sale+OE | $166.64 | -7,000 | 24,905 | -22% | -$1,166,493 | |||||
| D | 2018-09-04 | VCEL | Vericel Corp | Gilman Steven C | Dir | S - Sale+OE | $12.03 | -9,000 | 0 | -100% | -$108,270 | |||||
2018-09-04 | EDIT | Editas Medicine, Inc. | Bosley Katrine | Pres, CEO | S - Sale | $32.35 | -12,000 | 1,252,966 | -1% | -$388,210 | ||||||
2018-09-05 | BCDA | Biocardia, Inc. | Altman Peter | Pres, CEO | P - Purchase | $1.33 | +5,000 | 710,342 | +1% | +$6,650 | ||||||
| D | 2018-09-04 | ATRA | Atara Biotherapeutics, Inc. | Newell Joe | Chief Tech. Operations Officer | S - Sale+OE | $39.45 | -1,500 | 31,858 | -4% | -$59,178 | |||||
| M | 2018-08-31 | LIFE | Atyr Pharma Inc | Schimmel Paul | Dir | P - Purchase | $0.74 | +42,749 | 1,497,331 | +3% | +$31,461 | |||||
| D | 2018-08-31 | EDIT | Editas Medicine, Inc. | Hack Andrew A. F. | CFO | S - Sale+OE | $32.23 | -10,000 | 0 | -100% | -$322,300 | |||||
| D | 2018-08-31 | HSKA | Heska Corp | Lippincott Rod | EVP, Comp. Animal Health Sales | S - Sale+OE | $104.00 | -6,371 | 8,573 | -43% | -$662,584 | |||||
| D | 2018-08-30 | BLUE | Bluebird Bio, Inc. | Walsh Jeffrey T. | Chief Financial | S - Sale+OE | $175.40 | -20,000 | 35,495 | -36% | -$3,507,948 | |||||
2018-08-29 | ADAP | Adaptimmune Therapeutics Plc | Binder-Scholl Gwendolyn Knowlton | CTO | S - Sale | $10.25 | -25,000 | 0 | -100% | -$256,250 | ||||||
| D | 2018-08-30 | XLRN | Acceleron Pharma Inc | McLaughlin Kevin F | SVP, CFO, Treasurer | S - Sale+OE | $54.00 | -12,500 | 43,939 | -22% | -$675,000 | |||||
2018-08-29 | DNLI | Denali Therapeutics Inc. | Ho Carole | Chief Medical Officer | S - Sale | $18.04 | -17,500 | 290,265 | -6% | -$315,700 | ||||||
2018-08-29 | DNLI | Denali Therapeutics Inc. | Watts Ryan J. | Pres, CEO | S - Sale | $18.05 | -18,334 | 2,796,809 | -1% | -$330,929 | ||||||
2018-08-29 | CHRS | Coherus Biosciences, Inc. | Healy James | Dir | S - Sale | $20.50 | -25,000 | 2,868,221 | -1% | -$512,500 | ||||||
| D | 2018-08-29 | RGEN | Repligen Corp | Barthelemy Nicolas | Dir | S - Sale+OE | $54.44 | -6,580 | 4,186 | -61% | -$358,196 | |||||
| M | 2018-08-29 | LIFE | Atyr Pharma Inc | Schimmel Paul | Dir | P - Purchase | $0.74 | +164,411 | 1,454,582 | +13% | +$121,573 | |||||
2018-08-27 | SGEN | Seattle Genetics Inc /wa | Simpson Todd E | CFO | S - Sale | $74.23 | -5,427 | 173,565 | -3% | -$402,856 | ||||||
2018-08-27 | SGEN | Seattle Genetics Inc /wa | Siegall Clay B | Pres, CEO | S - Sale | $74.23 | -25,514 | 636,632 | -4% | -$1,893,950 | ||||||
2018-08-27 | SGEN | Seattle Genetics Inc /wa | Liu Jean I | GC, EVP, Leg Affairs | S - Sale | $74.23 | -4,123 | 56,741 | -7% | -$306,058 | ||||||
2018-08-27 | SGEN | Seattle Genetics Inc /wa | Himes Vaughn B | Chief Technical Officer | S - Sale | $74.23 | -5,530 | 159,376 | -3% | -$410,502 | ||||||
2018-08-27 | SGEN | Seattle Genetics Inc /wa | Cline Darren S | EVP, Commercial | S - Sale | $74.23 | -4,784 | 65,079 | -7% | -$355,125 | ||||||
| D | 2018-08-27 | ECL | Ecolab Inc. | Higgins Arthur J | Dir | S - Sale+OE | $149.76 | -8,700 | 16,863 | -34% | -$1,302,947 | |||||
| D | 2018-08-27 | RGNX | Regenxbio Inc. | Mills Kenneth T. | Pres, CEO | S - Sale+OE | $66.46 | -7,510 | 341,020 | -2% | -$499,118 | |||||
2018-08-28 | RGEN | Repligen Corp | Snodgres Jon | CFO | S - Sale | $52.79 | -14,460 | 20,899 | -41% | -$763,359 | ||||||
| D | 2018-08-27 | AERI | Aerie Pharmaceuticals Inc | Mitro Thomas A | Pres, COO | S - Sale+OE | $60.27 | -190,000 | 51,479 | -79% | -$11,451,006 | |||||
| D | 2018-08-27 | AST | Asterias Biotherapeutics, Inc. | Mulroy Michael H. | Pres, CEO | P - Purchase | $1.59 | +3,141 | 97,604 | +3% | +$5,000 | |||||
2018-08-27 | BCDA | Biocardia, Inc. | Altman Peter | Pres, CEO | P - Purchase | $1.46 | +1,500 | 705,342 | 0% | +$2,190 | ||||||
| DM | 2018-08-27 | HSKA | Heska Corp | Asakowicz Steve | EVP, Comp. Animal Health Sales | S - Sale+OE | $101.03 | -8,000 | 8,400 | -49% | -$808,247 | |||||
| D | 2018-08-24 | TECH | Bio-Techne Corp | Baumgartner Robert V | Dir | S - Sale+OE | $188.47 | -5,000 | 7,712 | -39% | -$942,334 | |||||
| M | 2018-08-24 | HALO | Halozyme Therapeutics Inc | Kirk Randal J | 10% | S - Sale | $18.08 | -644,998 | 14,092,771 | -4% | -$11,663,346 | |||||
| D | 2018-08-27 | MNTA | Momenta Pharmaceuticals Inc | Stoner Elizabeth | Dir | S - Sale+OE | $27.33 | -4,152 | 29,639 | -12% | -$113,474 | |||||
| M | 2018-08-23 | NK | Nantkwest, Inc. | Gorlin Steve | Dir | S - Sale | $3.07 | -50,000 | 518,000 | -9% | -$153,513 | |||||
| DM | 2018-08-23 | HSKA | Heska Corp | Lippincott Rod | EVP, Comp. Animal Health Sales | S - Sale+OE | $104.01 | -2,805 | 8,573 | -25% | -$291,743 | |||||
| D | 2018-08-23 | TECH | Bio-Techne Corp | Higgins John L | Dir | S - Sale+OE | $187.92 | -10,000 | 3,012 | -77% | -$1,879,173 | |||||
2018-08-22 | RGEN | Repligen Corp | Ryan Thomas F Jr | Dir | S - Sale | $51.44 | -2,366 | 4,988 | -32% | -$121,698 | ||||||
2018-08-21 | SGEN | Seattle Genetics Inc /wa | Siegall Clay B | Pres, CEO | S - Sale | $74.95 | -25,000 | 662,146 | -4% | -$1,873,750 | ||||||
| M | 2018-08-21 | HALO | Halozyme Therapeutics Inc | Kirk Randal J | 10% | S - Sale | $17.65 | -1,194,462 | 14,737,769 | -7% | -$21,085,138 | |||||
2018-08-21 | MNTA | Momenta Pharmaceuticals Inc | Kwon Young | SVP, Corporate Development | S - Sale | $27.25 | -528 | 111,343 | 0% | -$14,388 | ||||||
2018-08-21 | MNTA | Momenta Pharmaceuticals Inc | Kaundinya Ganesh Venkataraman | COO, CSO | S - Sale | $27.25 | -581 | 495,145 | 0% | -$15,832 | ||||||
2018-08-21 | MNTA | Momenta Pharmaceuticals Inc | Leicher Bruce | SVP, GC | S - Sale | $27.25 | -350 | 171,801 | 0% | -$9,538 | ||||||
2018-08-21 | MNTA | Momenta Pharmaceuticals Inc | Wheeler Craig A | Pres, CEO | S - Sale | $27.43 | -1,969 | 582,081 | 0% | -$54,010 | ||||||
| M | 2018-08-20 | ATRA | Atara Biotherapeutics, Inc. | Ciechanover Isaac E. | CEO | S - Sale | $36.37 | -7,800 | 886,891 | -1% | -$283,647 | |||||
2018-08-20 | EDIT | Editas Medicine, Inc. | Bosley Katrine | Pres, CEO | S - Sale | $30.17 | -12,000 | 1,264,966 | -1% | -$362,008 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |